From Spark to Inferno
China is emerging as an engine of therapeutic innovation, with its science now setting the pace in some of the most competitive areas of drug development, particularly in oncology.
Landmark deals, rapid early-stage data and a unique clinical ecosystem are reshaping how global companies source innovation, structure partnerships, and plan their oncology portfolios.
Ipsos’ latest white paper unpacks what this shift means for business development, strategy and investment teams.
This Point of View explores how Chinese biopharma innovation is reshaping the rules of engagement in global oncology, and where the next wave of opportunity is likely to emerge. Drawing on pipeline comparisons, deal case studies and ecosystem analysis, it helps decision makers distinguish signal from noise.
In our latest Ipsos white paper, our experts reveal:
- Examining the landmark deals that acted as catalysts
- Demonstrating how early data from China can ignite partnerships and global interest
- Exploring the unique ecosystem that enables this innovation
- Identifying the strategic challenges and how organisations can navigate this complex environment
